Carbon ion radiotherapy boost in the treatment of glioblastoma: a randomized phase I/III clinical trial

BACKGROUND: Glioblastoma (GBM) is a highly virulent tumor of the central nervous system, with a median survival < 15 months. Clearly, an improvement in treatment outcomes is needed. However, the emergence of these malignancies within the delicate brain parenchyma and their infiltrative growth pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Lin, Gao, Jing, Hu, Jiyi, Lu, Rong, Yang, Jing, Qiu, Xianxin, Hu, Weixu, Lu, Jiade J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383247/
https://www.ncbi.nlm.nih.gov/pubmed/30786916
http://dx.doi.org/10.1186/s40880-019-0351-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383247/
https://www.ncbi.nlm.nih.gov/pubmed/30786916
http://dx.doi.org/10.1186/s40880-019-0351-2

Ejemplares similares